ES2135576T3 - Uso de compuestos que se unen a actina para la fabricacion de un medicamento para reducir la viscosidad del contenido mucoide patologico de las vias respiratorias presente en el tracto respiratorio. - Google Patents

Uso de compuestos que se unen a actina para la fabricacion de un medicamento para reducir la viscosidad del contenido mucoide patologico de las vias respiratorias presente en el tracto respiratorio.

Info

Publication number
ES2135576T3
ES2135576T3 ES94914023T ES94914023T ES2135576T3 ES 2135576 T3 ES2135576 T3 ES 2135576T3 ES 94914023 T ES94914023 T ES 94914023T ES 94914023 T ES94914023 T ES 94914023T ES 2135576 T3 ES2135576 T3 ES 2135576T3
Authority
ES
Spain
Prior art keywords
respiratory tract
contents
actin
viscosity
pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914023T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of ES2135576T3 publication Critical patent/ES2135576T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE DIRIGE GENERALMENTE A METODOS PARA PROMOVER UN FLUJO DE AIRE NORMAL EN EL TRACTO RESPIRATORIO EN PACIENTES CON FLUJO DE AIRE RESTRINGIDO Y ACLARAMIENTO CILIAR PROVOCADO POR LA PRESENCIA DE CONTENIDOS PATOLOGICOS DE LAS VIAS AEREAS, Y PARTICULARMENTE CONTENIDOS MUCOSALES. LAS PROTEINAS QUE SE UNEN A LA ACTINA SE ADMINISTRAN AL INTERIOR DEL TRACTO RESPIRATORIO DE UN PACIENTE CON UNA CONDICION RESPIRATORIA PATOLOGICA QUE COMPRENDA LA PRESENCIA DE DICHOS CONTENIDOS. LA PROTEINA DE UNION A LA ACTINA SE UNE A LOS POLIMEROS DE ACTINA EN LOS CONTENIDOS Y HACE DESCENDER LA VISCOSIDAD. LAS PROTEINAS DE UNION A LA ACTINA TAMBIEN EVITAN QUE AL ACTINA SE UNA A LA DNASA I EXOGENA O ENDOGENA, INCREMENTANDO DE ESTA FORMA LA DEGRADACION DE POLIMEROS DE DNA EN LOS CONTENIDOS.
ES94914023T 1993-04-02 1994-04-04 Uso de compuestos que se unen a actina para la fabricacion de un medicamento para reducir la viscosidad del contenido mucoide patologico de las vias respiratorias presente en el tracto respiratorio. Expired - Lifetime ES2135576T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I

Publications (1)

Publication Number Publication Date
ES2135576T3 true ES2135576T3 (es) 1999-11-01

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914023T Expired - Lifetime ES2135576T3 (es) 1993-04-02 1994-04-04 Uso de compuestos que se unen a actina para la fabricacion de un medicamento para reducir la viscosidad del contenido mucoide patologico de las vias respiratorias presente en el tracto respiratorio.

Country Status (17)

Country Link
US (2) US5464817A (es)
EP (1) EP0692970B1 (es)
JP (2) JPH08510998A (es)
KR (1) KR100308679B1 (es)
CN (1) CN1107521C (es)
AT (1) ATE182790T1 (es)
AU (1) AU695033B2 (es)
BR (1) BR9405856A (es)
CA (1) CA2159205A1 (es)
DE (1) DE69419907T2 (es)
DK (1) DK0692970T3 (es)
ES (1) ES2135576T3 (es)
GB (1) GB2293102B (es)
GR (1) GR3031753T3 (es)
NO (1) NO953862D0 (es)
SG (1) SG49574A1 (es)
WO (1) WO1994022465A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
BR9510323A (pt) * 1995-02-24 1997-11-11 Genentech Inc Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
DE69716460T2 (de) 1996-12-04 2003-06-26 Renovo Ltd Wundheilung und behandlung von fibrose
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
BR0207725A (pt) * 2001-12-28 2004-03-23 Daiichi Suntory Biomedical Res Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
WO2006017816A2 (en) * 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
ATE513557T1 (de) * 2006-11-28 2011-07-15 Cls Therapeutics Ltd Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens
WO2008101084A2 (en) * 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
PL2708603T3 (pl) 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN108289932A (zh) 2015-05-22 2018-07-17 D·D·格恩金 胞外dna作为神经变性的治疗靶点
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
WO1991015770A1 (en) * 1990-04-11 1991-10-17 The General Hospital Corporation Therapeutic uses of actin-binding compounds
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
EP0692970B1 (en) 1999-08-04
DK0692970T3 (da) 1999-12-06
AU6625094A (en) 1994-10-24
NO953862L (no) 1995-09-29
BR9405856A (pt) 1996-03-05
KR100308679B1 (ko) 2001-11-30
DE69419907T2 (de) 1999-12-09
CN1107521C (zh) 2003-05-07
AU695033B2 (en) 1998-08-06
NO953862D0 (no) 1995-09-29
JPH08510998A (ja) 1996-11-19
DE69419907D1 (de) 1999-09-09
GB2293102B (en) 1996-10-09
GR3031753T3 (en) 2000-02-29
CA2159205A1 (en) 1994-10-13
ATE182790T1 (de) 1999-08-15
EP0692970A1 (en) 1996-01-24
SG49574A1 (en) 1998-06-15
JP2001302537A (ja) 2001-10-31
GB2293102A (en) 1996-03-20
GB9520020D0 (en) 1995-12-06
CN1122108A (zh) 1996-05-08
US5656589A (en) 1997-08-12
US5464817A (en) 1995-11-07
WO1994022465A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
ES2135576T3 (es) Uso de compuestos que se unen a actina para la fabricacion de un medicamento para reducir la viscosidad del contenido mucoide patologico de las vias respiratorias presente en el tracto respiratorio.
US20020107178A1 (en) Methods and preparations for curing clinically ill patients
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9909199A (pt) Composição fisiologicamente aceitável para injeção intra-celular para tratamento de distúrbios inflamatórios de juntas e método para preparação de uma composição injetável aquosa para tratamento de distúrbio inflamatório de junta
KR960000924A (ko) 인슐린 유사체 배합물
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
BR9809951A (pt) Método para tratamento da obesidade
BR9711573A (pt) Pepetìdeos c da insulina.
Samper Agrelo et al. Secretome analysis of mesenchymal stem cell factors fostering oligodendroglial differentiation of neural stem cells in vivo
PT750515E (pt) Acido hialuronico de baixo peso molecular contendo um peptido ou uma proteina
NO20050216L (no) Steroidkonjugater samt fremstilling og anvendelse derav
Hamidi et al. The effect of the central administration of the Neuropeptide VF on feed intake and its possible interactions with glutamate and opioid systems in broiler chicken
KR930700088A (ko) 흡입투여를 위한 타우린-기저 약학 조성물
Zhang et al. Melatonin attenuates phosgene-induced acute lung injury via the upregulation Wnt/β-catenin pathway
BR0002726A (pt) Uso e preparação contendo derivados de hemoglobina para a determinação do volume do plasma e/ou do sangue
SE9303612D0 (sv) New use
Nustede et al. On the effect of xenin and xenin fragments on exocrine pancreas secretion in vivo
AR003926A1 (es) Variante de adnasa humana i, ácido nucleico que la codifica, uso de dicha variante para preparar medicamentos útiles en el tratamiento de una enfermedad o afección pulmonar y una composición farmacéutica que contiene dicha variante.
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
AR003251A1 (es) Metodo de determinacion in vitro del grado de agregacion del peptido beta a4 y metodo para la determinacion del grado de inhibicion de la agregacion delpeptido beta a4 por un compuesto que inhibe la agregacion de dicho peptido.
SU1561263A1 (ru) Способ лечени инсулинозависимого сахарного диабета
BR9912018A (pt) Uso de uma molécula de ácido nucleico, molécula de ácido nucleico, composição farmacêutica, método de tratamento de distúrbios de proliferação celular associados com a cura de feridas em um mamìfero, incluido o ser humano, e, uso de um polipeptìdeo nab1 ou nab2
Buri Transnasal systemic medications. Fundamentals, developmental concepts and biomedical assessments: Yie W. Chien (ed.), Elsevier, Amsterdam, 1985, 226 pages, $53.75/Dfl. 145.00
Shaw et al. The effect of gastric surgery on intact neurotensin (NT) response to a fatty meal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 692970

Country of ref document: ES